0001654954-23-000150.txt : 20230105 0001654954-23-000150.hdr.sgml : 20230105 20230105162615 ACCESSION NUMBER: 0001654954-23-000150 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230105 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230105 DATE AS OF CHANGE: 20230105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AEHR TEST SYSTEMS CENTRAL INDEX KEY: 0001040470 STANDARD INDUSTRIAL CLASSIFICATION: INSTRUMENTS FOR MEAS & TESTING OF ELECTRICITY & ELEC SIGNALS [3825] IRS NUMBER: 942424084 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22893 FILM NUMBER: 23511677 BUSINESS ADDRESS: STREET 1: 400 KATO TERRACE CITY: FREMONT STATE: CA ZIP: 94539 BUSINESS PHONE: 5106239400 MAIL ADDRESS: STREET 1: 400 KATO TERRACE CITY: FREMONT STATE: CA ZIP: 94539 8-K 1 aehr_8k.htm FORM 8-K aehr_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

 

January 5, 2023

 

AEHR TEST SYSTEMS

(Exact name of registrant as specified in its charter)

 

California

000-22893

94-2424084

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

400 KATO TERRACE, FREMONT, CA 94539

(Address of principal executive offices, including zip code)

510-623-9400

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.01 per share

AEHR

The NASDAQ Capital Market

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On January 5, 2023, Aehr Test Systems, or the Company, issued a press release announcing the Company’s financial results for its second quarter of fiscal year 2023 ended November 30, 2022. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Form 8-K, including the exhibit attached hereto, are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

  

Exhibit No.

 

Description

99.1

 

Press Release of Aehr Test Systems dated January 5, 2023 entitled “Aehr Reports 54% Revenue Growth Year over Year in Second Quarter of Fiscal 2023 on Strength of Semiconductor Test and Burn-In Sales for Electric Vehicles.”

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Aehr Test Systems

(Registrant)

    

Date: January 5, 2023

By:

/s/ Kenneth B. Spink

 

 

Kenneth B. Spink

 
  

Vice President of Finance and

 
  

Chief Financial Officer

 

 

 

3

 

 EX-99.1 2 aehr_ex991.htm EX-99.1 aehr_ex991.htm

EXHIBIT 99.1

 

 

FOR IMMEDIATE RELEASE

 

Contacts:

 

Aehr Test Systems

 

MKR Investor Relations Inc.

Ken Spink

 

Todd Kehrli or Jim Byers

Chief Financial Officer

 

Analyst/Investor Contact

(510) 623-9400 x309

 

(213) 277-5550

 

 

aehr@mkr-group.com

 

Aehr Reports 54% Revenue Growth Year over Year in Second Quarter of Fiscal 2023

on Strength of Semiconductor Test and Burn-In Sales for Electric Vehicles

 

Adds Two New Silicon Carbide Customers During the Quarter

 

Fremont, CA (January 5, 2023) – Aehr Test Systems (NASDAQ: AEHR), a worldwide supplier of semiconductor test and reliability qualification equipment, today announced financial results for its second quarter of fiscal 2023 ended November 30, 2022.

 

Fiscal Second Quarter Financial Results:

 

 

·

 Net sales were $14.8 million, up 54% from $9.6 million in the second quarter of fiscal 2022.

 

·

 GAAP net income was $3.7 million, or $0.13 per diluted share, compared to GAAP net income of $717,000, or $0.03 per diluted share, in the second quarter of fiscal 2022.

 

·

 Non-GAAP net income was $4.5 million, or $0.16 per diluted share, which excludes the impact of stock-based compensation, compared to non-GAAP net income of $1.4 million, or $0.05 per diluted share, in the second quarter of fiscal 2022.

 

·

 Bookings were $10.8 million for the quarter ended November 30, 2022.

 

·

 Backlog as of November 30, 2022 was $15.5 million. Effective backlog, which includes all orders since the end of the second quarter, is over $23.5 million.

 

Fiscal First Six Months Financial Results:

 

 

·

 Net sales were $25.5 million, up 67% from $15.3 million in the first six months of fiscal 2022.

 

·

 GAAP net income was $4.3 million, or $0.15 per diluted share, compared to GAAP net income of $1.4 million, or $0.05 per diluted share, in the first six months of fiscal 2022.

 

·

 Non-GAAP net income was $5.8 million, or $0.20 per diluted share, which excludes the impact of stock-based compensation, compared to non-GAAP net income of $1.0 million, or $0.04 per diluted share, in the first six months of fiscal 2022, which excludes the impact of stock-based compensation and forgiveness of loans from the Paycheck Protection Program.

 

An explanation of the use of non-GAAP financial measures and a reconciliation of Aehr’s non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying tables.

 

 

 

 

Aehr Test Systems Reports Second Quarter Fiscal 2023 Financial Results

January 5, 2023

Page 2 of 7

 

Gayn Erickson, President and CEO of Aehr Test Systems, commented:

 

“We had a very solid quarter, reflecting strong sequential and year-over-year growth in revenue and net income, both ahead of consensus estimates. Our momentum in silicon carbide wafer level burn-in continues to grow. We see this momentum continuing for the next several years as companies are adding significant capacity in silicon carbide semiconductors to address the incredible forecasted demand, particularly for the electric vehicle and electric vehicle charger markets.

 

“Forecasts from William Blair estimate that the silicon carbide market for devices in electric vehicles alone, such as traction inverters and on-board chargers, is expected to grow from 119,000 6-inch equivalent silicon carbide wafers for electric vehicles in 2021 to more than 4.1 million 6-inch equivalent wafers in 2030, representing a compound annual growth rate (CAGR) of 48.4%. Total 6-inch equivalent silicon carbide wafers for all current addressable markets are expected to grow to nearly 7 million 6-inch equivalent silicon carbide wafers in 2030.

 

“We are excited to have added two new customers for silicon carbide test and burn-in during the quarter. The first is a major silicon carbide semiconductor supplier that purchased our FOX-NP™ dual wafer test and burn-in system used for engineering and device qualification during the quarter, and after the quarter closed has since placed their first orders for two of our FOX-XP multi-wafer systems for volume production test and burn-in of their silicon carbide wafers, including the order we announced today. This customer serves several significant markets including the electric vehicle industry and selected our FOX-XP multi-wafer test and burn-in system configured with our new fully integrated and automated WaferPak™ Aligner for high volume hands-free operation. They have indicated to us they plan to order a significant number of FOX-XP systems for volume production of their silicon carbide devices at facilities around the world to meet the rapidly expanding forecasted market demand for silicon carbide devices for electric vehicles and other industrial markets. The second new customer added this quarter is a multibillion-dollar annual revenue global manufacturer of semiconductors who purchased our FOX-NP test and burn-in system for qualification of their silicon carbide devices for multiple markets including electric vehicles. We anticipate that this customer will move to high volume production using our FOX-XP systems after customer qualifications.

 

“Adding two new customers now provides more optimism about our ability to gain significant market share of the test and burn-in market for silicon carbide devices. These customers expand our penetration beyond our initial lead silicon carbide wafer level burn-in customer that continues to ramp their capacity and use of our FOX-XP multi-wafer test and burn-in systems and WaferPaks. Our lead customer continues to forecast orders for significant numbers of FOX-XP systems and WaferPak Contactors over the next several years.

 

“In addition to the customers that have now placed initial orders with Aehr for silicon carbide wafer level test and burn-in systems, our ongoing benchmarks and evaluations with multiple prospects made great progress during the quarter. These include significant market leaders in silicon carbide as well as several companies entering the silicon carbide power semiconductor space. We expect several of these companies to place their initial orders with us before the end of this fiscal year ending May 31, 2023. We also continue to see very positive responses from our discussions with a number of new potential customers in silicon carbide this quarter and have also begun detailed discussions with gallium nitride semiconductor suppliers from around the world. Both silicon carbide and gallium nitride semiconductors address the high voltage power semiconductor markets that are significant opportunities for our FOX wafer level test and burn-in systems and WaferPak full wafer contactors. Both device types are forecasted to grow significantly over the next several years and into the future.

 

 

 

 

Aehr Test Systems Reports Second Quarter Fiscal 2023 Financial Results

January 5, 2023

Page 3 of 7

 

“We are also seeing a strong recovery of our silicon photonics wafer level test and burn-in business after the weakness we saw during the pandemic. Halfway through this fiscal year, we have shipped over $5 million in systems, upgrades and WaferPaks to silicon photonics customers, which is over 300% of last fiscal year’s first half revenue for silicon photonics. This jump in revenue is also spread across multiple customers and much of it is for new product designs and qualifications. We have systems installed at over a half dozen customers testing silicon photonics devices used in 5G infrastructure, data and telecommunications transceivers, and a few yet to be announced applications that we are very excited about. With multiple market leaders announcing plans to integrate photonics transceivers into their microprocessors, graphics processors, and chipsets, we believe silicon photonics will become a significant market for wafer level test and burn-in over the next several years.

 

“Looking ahead, we continue to believe that we will receive production orders from additional silicon carbide companies beyond our current customers and begin shipping systems to meet their production capacity by the end of our current fiscal year that ends May 31, 2023. We are very optimistic for a strong second half of this fiscal year and believe the momentum will continue into our fiscal 2024.”

 

Fiscal 2023 Financial Guidance:

 

For the fiscal year ending May 31, 2023, Aehr is reiterating its previously provided guidance for total revenue to be $60 million to $70 million, with strong profit margins similar to last fiscal year. Aehr also continues to expect bookings to grow faster than revenues in fiscal 2023 as the ramp in demand for silicon carbide in electric vehicles increases exponentially throughout the decade.

 

Management Conference Call and Webcast

 

Aehr Test Systems will host a conference call and webcast today at 5:00 p.m. Eastern (2:00 p.m. PT) to discuss its second quarter fiscal 2023 operating results. To access the live call, dial +1 877-270-2148 (US and Canada) or +1 412-902-6510 (International) and ask to join the Aehr Test Systems earnings call. In addition, a live and archived webcast of the conference call will be available over the Internet at www.aehr.com in the Investor Relations section and may also be accessed by clicking here. A replay of the conference call will also be available via telephone beginning approximately two hours after conclusion of the call and will remain available for one week. To access the call replay, dial +1 877-344-7529 (US and Canada) or +1 412-317-0088 (International) and enter replay passcode 2248525.

 

About Aehr Test Systems

 

Headquartered in Fremont, California, Aehr Test Systems is a worldwide provider of test systems for burning-in semiconductor devices in wafer level, singulated die, and package part form, and has installed over 2,500 systems worldwide. Increased quality and reliability needs of the Automotive and Mobility integrated circuit markets are driving additional test requirements, incremental capacity needs, and new opportunities for Aehr Test products in package, wafer level, and singulated die/module level test. Aehr Test has developed and introduced several innovative products, including the ABTSTM and FOX-PTM families of test and burn-in systems and FOX WaferPakTM Aligner, FOX WaferPak Contactor, FOX DiePak® Carrier and FOX DiePak Loader. The ABTS system is used in production and qualification testing of packaged parts for both lower power and higher power logic devices as well as all common types of memory devices. The FOX-XP and FOX-NP systems are full wafer contact and singulated die/module test and burn-in systems used for burn-in and functional test of complex devices, such as leading-edge silicon carbide-based power semiconductors, memories, digital signal processors, microprocessors, microcontrollers, systems-on-a-chip, and integrated optical devices. The FOX-CP system is a new low-cost single-wafer compact test and reliability verification solution for logic, memory and photonic devices and the newest addition to the FOX-P product family. The WaferPak Contactor contains a unique full wafer probe card capable of testing wafers up to 300mm that enables IC manufacturers to perform test and burn-in of full wafers on Aehr Test FOX systems. The DiePak Carrier is a reusable, temporary package that enables IC manufacturers to perform cost-effective final test and burn-in of both bare die and modules. For more information, please visit Aehr Test Systems’ website at www.aehr.com.

 

 

 

 

Aehr Test Systems Reports Second Quarter Fiscal 2023 Financial Results

January 5, 2023

Page 4 of 7

 

Safe Harbor Statement

 

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or Aehr’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates,” “going to,” "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," “sees,” or "continue," or the negative of these words or other similar terms or expressions that concern Aehr’s expectations, strategy, priorities, plans, or intentions. Forward-looking statements in this press release include, but are not limited to, Aehr’s ability to generate bookings and revenue increases in the future, including the third quarter of fiscal 2023; future requirements and orders of Aehr’s new and existing customers; bookings forecasted for proprietary WaferPakTM and DiePak consumables across multiple market segments; the temporary nature of customer pushouts; shipping timelines for products and follow-on capacity orders; the growth of Aehr’s systems and consumables, including as a percentage of total sales; financial guidance for fiscal 2023, including related to revenue and profitability, and expectations regarding fiscal 2023; Aehr’s ability to expand its number of customers using its FOX-PTM solutions; the ability to secure potential customer engagements; and expectations related to long-term demand for Aehr’s productions and the attractiveness of key markets. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in Aehr’s recent 10-K, 10-Q and other reports filed from time to time with the Securities and Exchange Commission. Aehr disclaims any obligation to update information contained in any forward-looking statement to reflect events or circumstances occurring after the date of this press release.

 

– Financial Tables to Follow –

 

 

 

 

Aehr Test Systems Reports Second Quarter Fiscal 2023 Financial Results

January 5, 2023

Page 5 of 7

 

AEHR TEST SYSTEMS AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

Nov 30,

 

 

Aug 31,

 

 

Nov 30,

 

 

Nov 30,

 

 

Nov 30,

 

 

 

2022

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

 $ 14,815

 

 

 $ 10,671

 

 

 $ 9,611

 

 

 $ 25,486

 

 

 $ 15,257

 

Cost of sales

 

 

 6,904

 

 

 

 6,190

 

 

 

 5,092

 

 

 

 13,094

 

 

 

 8,457

 

Gross profit

 

 

 7,911

 

 

 

 4,481

 

 

 

 4,519

 

 

 

 12,392

 

 

 

 6,800

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

 2,875

 

 

 

 2,525

 

 

 

 2,489

 

 

 

 5,400

 

 

 

 4,442

 

Research and development

 

 

 1,551

 

 

 

 1,498

 

 

 

 1,313

 

 

 

 3,049

 

 

 

 2,634

 

Total operating expenses

 

 

 4,426

 

 

 

 4,023

 

 

 

 3,802

 

 

 

 8,449

 

 

 

 7,076

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from operations

 

 

 3,485

 

 

 

 458

 

 

 

 717

 

 

 

 3,943

 

 

 

 (276 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

 263

 

 

 

 121

 

 

 

 (1 )

 

 

 384

 

 

 

 (10 )

Income from forgiveness of PPP loan

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 1,698

 

Other (expense) income, net

 

 

 (5 )

 

 

 24

 

 

 

 35

 

 

 

 19

 

 

 

 58

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income before income tax expense

 

 

 3,743

 

 

 

 603

 

 

 

 751

 

 

 

 4,346

 

 

 

 1,470

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax expense

 

 

 (18 )

 

 

 (14 )

 

 

 (34 )

 

 

 (32 )

 

 

 (57 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 $ 3,725

 

 

 $ 589

 

 

 $ 717

 

 

 $ 4,314

 

 

 $ 1,413

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 $ 0.14

 

 

 $ 0.02

 

 

 $ 0.03

 

 

 $ 0.16

 

 

 $ 0.06

 

Diluted

 

 $ 0.13

 

 

 $ 0.02

 

 

 $ 0.03

 

 

 $ 0.15

 

 

 $ 0.05

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in per share calculations:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 27,579

 

 

 

 27,242

 

 

 

 26,205

 

 

 

 27,410

 

 

 

 25,102

 

Diluted

 

 

 29,080

 

 

 

 28,788

 

 

 

 28,342

 

 

 

 28,934

 

 

 

 26,849

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-more-

 

 

 

 

Aehr Test Systems Reports Second Quarter Fiscal 2023 Financial Results

January 5, 2023

Page 6 of 7

 

AEHR TEST SYSTEMS AND SUBSIDIARIES

Reconciliation of GAAP and Non-GAAP Results

(in thousands, except per share data)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

Nov 30,

 

 

Aug 31,

 

 

Nov 30,

 

 

Nov 30,

 

 

Nov 30,

 

 

 

2022

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP net income

 

 $ 3,725

 

 

 $ 589

 

 

 $ 717

 

 

 $ 4,314

 

 

 $ 1,413

 

Stock-based compensation expense

 

 

 793

 

 

 

 710

 

 

 

 718

 

 

 

 1,503

 

 

 

 1,306

 

Income from forgiveness of PPP loan

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 (1,698 )

Non-GAAP net income

 

 $ 4,518

 

 

 $ 1,299

 

 

 $ 1,435

 

 

 $ 5,817

 

 

 $ 1,021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP net income per diluted share

 

 $ 0.13

 

 

 $ 0.02

 

 

 $ 0.03

 

 

 $ 0.15

 

 

 $ 0.05

 

Non-GAAP net income per diluted share

 

 $ 0.16

 

 

 $ 0.05

 

 

 $ 0.05

 

 

 $ 0.20

 

 

 $ 0.04

 

Shares used in GAAP diluted shares calculation

 

 

 29,080

 

 

 

 28,788

 

 

 

 28,342

 

 

 

 28,934

 

 

 

 26,849

 

Shares used in non-GAAP diluted shares calculation

 

 

 29,080

 

 

 

 28,788

 

 

 

 28,342

 

 

 

 28,934

 

 

 

 26,849

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP net income is a non-GAAP measure and should not be considered a replacement for GAAP results. Non-GAAP net income is a financial measure the Company uses to evaluate the underlying results and operating performance of the business. The limitation of this measure is that it excludes items that impact the Company's current period net income. This limitation is best addressed by using this measure in combination with net income (the most directly comparable GAAP financial measure). These measures are not in accordance with GAAP and may differ from non-GAAP methods of accounting and reporting used by other companies.

 

We believe these measures enhance investors’ ability to review the company’s business from the same perspective as the Company’s management and facilitate comparisons of this period’s results with prior periods.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-more-

 

 

 

 

Aehr Test Systems Reports Second Quarter Fiscal 2023 Financial Results

January 5, 2023

Page 7 of 7

 

AEHR TEST SYSTEMS AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

November 30,

 

 

August 31,

 

 

May 31,

 

 

 

2022

 

 

2022

 

 

2022

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 $ 18,874

 

 

 $ 36,147

 

 

 $ 31,484

 

Short-term investments

 

 

 17,710

 

 

 

 -

 

 

 

 -

 

Trade and other accounts receivable, net

 

 

 10,156

 

 

 

 5,116

 

 

 

 12,859

 

Inventories

 

 

 17,972

 

 

 

 17,233

 

 

 

 15,051

 

Prepaid expenses and other

 

 

 823

 

 

 

 833

 

 

 

 613

 

Total current assets

 

 

 65,535

 

 

 

 59,329

 

 

 

 60,007

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

 1,263

 

 

 

 1,322

 

 

 

 1,203

 

Operating lease right-of-use assets

 

 

 561

 

 

 

 740

 

 

 

 917

 

Other assets

 

 

 184

 

 

 

 187

 

 

 

 201

 

Total assets

 

 $ 67,543

 

 

 $ 61,578

 

 

 $ 62,328

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

 $ 3,949

 

 

 $ 3,387

 

 

 $ 4,195

 

Accrued expenses

 

 

 2,566

 

 

 

 2,479

 

 

 

 3,610

 

Operating lease liabilities, short-term

 

 

 551

 

 

 

 741

 

 

 

 794

 

Customer deposits and deferred revenue, short-term

 

 

 3,680

 

 

 

 3,292

 

 

 

 2,415

 

Total current liabilities

 

 

 10,746

 

 

 

 9,899

 

 

 

 11,014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating lease liabilities, long-term

 

 

 65

 

 

 

 73

 

 

 

 212

 

Deferred revenue, long-term

 

 

 25

 

 

 

 47

 

 

 

 69

 

Other liabilities

 

 

 40

 

 

 

 41

 

 

 

 44

 

Total liabilities

 

 

 10,876

 

 

 

 10,060

 

 

 

 11,339

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total shareholders' equity

 

 

 56,667

 

 

 

 51,518

 

 

 

 50,989

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total liabilities and shareholders' equity

 

 $ 67,543

 

 

 $ 61,578

 

 

 $ 62,328

 

 

# # #

 

 

 

 EX-101.SCH 3 aehr-20230105.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 aehr-20230105_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Local Phone Number Security 12b Title Trading Symbol Security Exchange Name EX-101.CAL 5 aehr-20230105_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 aehr-20230105_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 aehr-20230105_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 8 aehr_ex991img1.jpg begin 644 aehr_ex991img1.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Jan. 05, 2023
Cover [Abstract]  
Entity Registrant Name AEHR TEST SYSTEMS
Entity Central Index Key 0001040470
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Jan. 05, 2023
Entity File Number 000-22893
Entity Incorporation State Country Code CA
Entity Tax Identification Number 94-2424084
Entity Address Address Line 1 400 KATO TERRACE,
Entity Address City Or Town FREMONT
Entity Address State Or Province CA
Entity Address Postal Zip Code 94539
City Area Code 510
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Local Phone Number 623-9400
Security 12b Title Common Stock, par value $0.01 per share
Trading Symbol AEHR
Security Exchange Name NASDAQ
XML 10 aehr_8k_htm.xml IDEA: XBRL DOCUMENT 0001040470 2023-01-05 2023-01-05 iso4217:USD shares iso4217:USD shares 0001040470 false 8-K 2023-01-05 AEHR TEST SYSTEMS CA 000-22893 94-2424084 400 KATO TERRACE, FREMONT CA 94539 510 623-9400 false false false false false Common Stock, par value $0.01 per share AEHR NASDAQ EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://aehr.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-0540-DocumentPeriodEndDate-Value] In submission type 8-K, DocumentPeriodEndDate value "2023-01-05", is not equivalent to header element periodOfReport value "01-04-2023" in the Required Context. aehr_8k.htm 1 aehr_8k.htm aehr-20230105.xsd aehr-20230105_cal.xml aehr-20230105_def.xml aehr-20230105_lab.xml aehr-20230105_pre.xml aehr_ex991.htm http://xbrl.sec.gov/dei/2022 true true JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "aehr_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "calculationLink": { "local": [ "aehr-20230105_cal.xml" ] }, "definitionLink": { "local": [ "aehr-20230105_def.xml" ] }, "inline": { "local": [ "aehr_8k.htm" ] }, "labelLink": { "local": [ "aehr-20230105_lab.xml" ] }, "presentationLink": { "local": [ "aehr-20230105_pre.xml" ] }, "schema": { "local": [ "aehr-20230105.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "aehr", "nsuri": "http://aehr.com/20230105", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_8k.htm", "contextRef": "From2023-01-05to2023-01-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://aehr.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_8k.htm", "contextRef": "From2023-01-05to2023-01-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 18 0001654954-23-000150-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-23-000150-xbrl.zip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

4T\@JO409LSV*2'=0WS8U?4(=]$-KGI]G,RKWV%= MA?A,ZL0X\L:XQ-I5(>^.[C&V6,SV6.&$M.D!:9&1JY+L8.^)S> CI[-BE"<2 M)Y8M#RP+K7@X]GL9J!E>X'Q29O&Y(0]4 ML7*1:BY5CF6$=* K%WB677=E4GEY=B'0B?UOWM@[V?8P'&.ZZB=HD$W9IA2[ M/.-+0YR&X)VW(;A@U0/\3I(@)+W]P H1HBKPA7(GZ+?>H%=8] >\BU]?U5@N MA0/N0[%;N>*O)BSUYX]UOM:]JH&2;VQS7^D2\+,(-^K^JL1JI_[0#Z0VE/_- MYI=.K<5Z-^P^*LG++J\*W1YN'06T'/.QP@VLC[*RR,E54?ZEF#$@L,+*%F)[ MFM;%3$ND;G!]E)*5WJY*>20YBYG!@O89ERS%*"]&7*1SX^NC?BQW=56X P5V MB %/ ?G=+GN37[U.IV47U55Z-]@^*LK++GU"[VN] /5?T1=$N0V C[+2U?%5 MA\$^S^.#5(K*&R?G*C?,/DK',D?77:\A7N#)8QTU)V/[]*]DM3Y3N6'U41R6 M.;HJUK&B]N'\:)U-9,D9\$3B]FS%1_U7Z,7+).VMXI2*&90_;BU6NK'U4>55 M.3M#?!>>Y?^$&^R_,C9[[)O]I\+[?P%02P,$% @ 1X,E5DJI _C[#@ M$5L L !A96AR7SAK+FAT;>U<;7?:.!;^*UIFNTG/B;$AT :2L(<2TF7; MD PP;_MEC[ %:&ILCR0GL+]^[Y5LL($DI UIF6D_--BZTI7NFYZK%Y_]:%4= J$!6[H\6!\7HC5R#HI_+-Q-E% !92!K//9>6&B5%2W[;N[ MN^)L*/QB*,9VV2D=VSSP>"Z.P]M'VSFQCDMI.VXL!(QNOFA(]R9M*2V%BN5R4B7'\NY8 M][Q4J]7L&8HD;7XN*H3!%G7"P%JI)]CH7JF\L:%T87 RK)1+;Q\2 MH:%(*\32$J'/EO8RHG*HJ=.2W(C=, Z4N,\.36&N0JS$O9VIV5":$DJA+!S^ MAIXLBG(M@[Q6*FP6)]1Q+*=DE4L95AN9Y#LNK3&ET4:Y8$&.F++)B"T@-%6H)1Q3PR MG!.,#E=4*B8LJW$V98H29&*Q/V)^>UYHA8&"&M8 QED@KGDZ+R@V4[9Q<[MQ M9AO>P]";$ZGF/C,$%O7Y.*C[;*1.1U"S7G(B112?,DD"=D=$.*4!]-SCMTFU M X_+R*=SM&)VNG4;IP>$>^<'.)2+SL\'C3,^JV.7F# _N>>Q0/^$=KO&[DE MI]!/\+=Z.P 1S5LP,$']3N"QV0.F=VCL7]')N@!0\U<>G3\=:$ECV:VTWK)LT4WO'M*T)'U.F=@Y<:3MQ $W MHOFI?[&0P911&0O62,)J'>NU,2+&A D1: M.O19&NXP-%F2_X_52]'L](Y[:@*1RGD%$E(8%N$/5%1>2O_NNG?1[EGOK@># MZZLZJ48S(D.?>Z=0P59H'YK^H3KES77LA)^M^]^TZT3!\9#5B-QH?&/'TIOG-,S.WI^#BZX)1,X M*JE$&(P;/W4[@_8%Z0^:@W;_S$[>O@SO?KOU4Z\SZ+3[I-F](.U?6_]J=M^W M2>OZZJK3[W>NNR_FU;ZY[ M@Q>VX9M8R)@"#E4AZ3,7,U)2.B;7/5*J'GJO23@B@PG#HEAPQ8%+>^9.:#!F MI.DJ+"[5CBN[[?0+QCD$"#BH'HM"H_:1!3,2?5(X+M/N#T+R+G') 8 MA@(PA@71QH4H7W=.,Q$0N:ZV-*5BS ,+?]=IK,+TA>#C2?+&H)%*]14D&LSW M(^J9%2PG"TY2_A.F*Y8 D10> !\_./H?*65!R.X-YL&IX4NMR:2!/3;F$E?+ M5!=*"HUF^U\] KAC0/J_]0?MJ_X&>DLH5,'PGDZ?L7%M6A=D@2"A*J M"1/D=P#+TN,&3N\6P<&U&(1W,+=?]MI7(,E5CD?/S%('N6MQ ZB"X[9LH]7<\2!O0L Q_G]XI$$. MS!35X]JS@?YOP( /DW%B9A )$"J/J$_8C+FQXK>8,( W,WF$(=Z/$1Z3__$( M.NZQ[Z[]O*Z-_M04C!I+JY;6=A"M+V;Q,03YW4S"8($FWP!9#2+'G\JFEVG[ M/WXX*9?>GDJ@\UF$ R>!'GG6H"D(_:]AT=M9X]V1TAY>0@ +",>L< M0N>C\$A-? -]CXA9-@8@AI,'\:E,UU&__FK'CCBT)LS]1" C(#2"7!PB/&8) MPW!&ALP/[U H6(BB(R?6!S+B/GH$E^ >BH%)>+@L+_DT]A4-6!A+?TXD6(P< MS77-I$(X!*X&](6FRLX )F( Z M =2-3?;2+):+IKNOZWNZVIUP^.+X_8O@"M2".4T<)"A;KB^]X'&0(049@QG/ M<&"UMY7*Z6J(-^/-_D_,GX0+]"_+AD29C9I>#,E.I5Q-=*OR&S2X+W-8>DM: MESU2/G:*0+BO^Q3/I;E^Z',7I!.,K\ #P0W]YU-;HKPE"S)->*SKK%2A5JF< M45MN,VVAM(I3-)1_=;W="(;>AH>8].8PQD1Q/1H!=GIN_0$KR\WP>M3_2A7/ M*A\.7V^G34/[79\Y?7:DC)GXMK1ZS*S*H;N=5A/:/==J)_!0'@R/H+H:L4RI M^$3N)DRO9:[ "0 G &-!F+B=,R9C$=ZI"8HU0HA!)?'8"'"LWM$R\Y1339'' MRB1E#@\EQ%SOA46X%X9PTNBF/+3*&]K:=")AT2CJ:5DOTVQQ MO[76OD<#S[0 DS;_7K?>,HU_KGONMZ0[HP[#UX#X!)P#\F 73WL' MH0XYL62:"G@FO4K;*^5"0+?>ZE_A;):296&'TP<9\L M](R>R )$L)N49],QLR=MN"?E9C-]?5?LE^OC]+F-^Q+3]FP M3_JFPNC^CNM>K)H^K:[NB9M [7>L8X"T.]B?SPT M \QY-K](L:,^K;F6*F H2P^C=9O]B^:/:YO'+1IQ!1CV"@ T4U]]5^ YKQ7= M2X^:;FO7ANNP.8&O? ^V@X$4NQ/6$Z&K1_'5B=[D6[.S#: MV'(O;ZGZ@XB.F344C'ZRZ @LNDZH?T?G\N )1W_7>OZGV7Y*]] [BDU)N>B4 MBZ3'9.PK?=[@.F(B606#-)%<+C+(5@@9+184]_U:1\+A.B K]PR.2)--!!G@ MC8[^'.#45!YA.HU97VN1V./JI$E>6?+'5O]J2!66DQTEE(; )06H5'> R!#!F2C6(1<*FE">H" M .?[>KUFR(C'V!3>H[++$%JYSSS]NW2JM1S%(@HET^ZU6%$X>7#ULW*$.J-3 MK?F%#69788X6QTKO.&A;QL/?H6FC649\3H?<-ZUJ/E2EK'7%Y=E0\XV!Q:5P ME!0N)"5;R/?N)":+M%MT$R9X%IEK#5IF0Y2V-E7-6GZ' OPL3=Q%WEGR78XJ7!S)AV/93GNKSUA6#H M:8?Y:Z]V >K3I;RE_:5303=<6A>Y_WY".=^M%8GIQQ&=7^V362RL.]$L M9V)/O>KP(D*Y8-(5/,((^:3S=:=#ZGX:"YC[/\N=+N[&'K?R&XT^.DEX >FIS4H1SP] MVZU@/J(_,>(OIV]=SP B2:J55_#[E@4Q(V;/B_R&L R@F#"_8(;J&P3WXQ+! M71H$I]O7"T$PFXVAK@8 4X[DL:O"I'\8[]\!NK Z0$I]9K!A&_>$,//^F4VX M"V^+":;(Z^];2(+W*+M<"39#'[PW$VK(INQS9VY:_HR;J-^3VVV_"])YWVT. M?NKM^H,D+P:ALM]D,'O(?\1<))AQN^,/1YJHE]]\]F( XBZ-<<-8)TGF^"VR M :PNH0=0$)J+R$,&&'Z$8!T;TME!0H )4QQ '=T'N.V;]ZR,OY M:O9,=WFGL&AM]MR)D)?\,M<#-EW4VS*Z)Q]2>/OJM+ JMQS%\:,$SF,4I>HJ MQ8M_3& I/?RJ1GT-V>3D^&Y>?P1XK\Z%.[4O6]KD PL"!JCH79'T(QY\>KK> M=PQ=OV$XO)3D@U)\BGWFK7WU<8\E@C_^ZHF8G3#$3[TV_@]02P,$% @ 1X,E5BI MMC<;+0 NDD# X !A96AR7V5X.3DQ+FAT;>U]:W?;-M;N7\%QVVFR#N60 MNEBRG7H=)582SS2.:ZFG[7PY"R(AB0U%JKS8T?OKS]X ;Q+I:R0+(M%9X]@2 MR0WLYP&P;P#?SL*Y<_9VQJAU]C:T0X>=43;S_Q_[=GQL',*7;]^(3]_^KT;C MW#.C.7-#8OJ,ALPB46"[4S(X_]B__DR#D/F-QMG;-^)A8\]:DB!<.NR7@]'@ MSU&C_^O%Q\L3XK!)>$H^?+DU1A> M_'<@+A6W-3[T/U_\^M?)^HVGY'/_^N,%B- 7WTY)R+Z%#>K84_?$MZ>S\!0> M'(2^YT[/!G]^NGAW,2+'QX?&VS?QAV_?+,[(UD3_RQT'B]/MR. :A=[9\RD) M?/.7@PQ!^,@X_'LQ/=A2]V+1V^S=WU$0VI,E=C Z^_#EFEQ\_CPXO^B/!N1Z M\.N@/QR\?1-MJ7N9[!?J8 MK(N=4W]JNR<@](Y>Y"\@;T,Z=ECRU=CS+1C4P8*:,-!/]-,UN>M,N+6M< 9? MZ3\=$),YSH):%MSXRX'.'^TGSYTQ'!8G1B>6:25?B >T])].#UY$T7T8*63$ M@I ,ES!_S0.RHG&8_*R2]C77V_?=<*2"7J37G_\#H\B]@6Y[/KEF#@UMSPW@ M(_.PV'WXX=\/WE;;_!_FDN'"=K^2._6T)]H?>99%_@.$O^W/2?OELP/ M9-'T^YG-)N2#[5+7M*E#ODPFMLG\O==[WZ4.#.XW*>/CV?69>G]FKU]U#/TU M.6JV&L=M72??6OIQ,ASOF'.VK^KG=J5IM%Z39K?;Z'0Z^LNJ<3L]VLY3T0S[ M/_.O?F/J>]'BT/3FJ[J"'[C8KJ_M^4=LQ^ PP89G_I:MFE3(REI[S1:>'P:D MT\Y('__[$WQYP]R(D8^^=QO.R%^,^L2[@2F(_V;#0L!,S[7(;Q'UX=G$P^DJ M,&&N:NK-%MFR*5_HD <-"GWF3J&MT)1"AX9L;F-[(Q-G'6YE4&C]N\AW&Q=P M+W5 \ 2^&CC,#'W;)/^7S6P3/GVIGKP,_FQ^UK>L@(QN/7()-PYM!_5"WE-_ M;%N,O(>IVIO#2DC.(Q\=RG#&$HS?OH&[=Z&%9X[Y!/L//IO#+1IYWR>O_DU= MZ,V2=#1.U-<95?[U0Z]I&*>D:(>^NNP/S_N_G9#^X-/U:XU0H!>OD="SZ!(N=[W( M-<&=GZ1KO\^"R D%.VWX-Q #[Y]LX$UR X^Y%MQ]"4-U/H9O6SKO9_-PBT[+ M]\(C6K\VGV2VS[7HOW3^U[K#A8)/RJ(HFW+%VEOS= IR8*(/@:1.W+_06VQ$ M]%N\<.49\4W!!KVCZ/&"]'CG>5]A;4MG M8CV;B;D%@UI/U'VWK:+T_F2]4_.KXTT)C$1@<4&G8H@:G6R,'I+!9 *^CGW# MR%C, N4_:GLS^?;G\U.?BT$^_.HF]B?, 1;ZP;HA),O /+- M!?G4.K0=$[2=Z3XU44K-@X=,T*?:&0KA%S1$.WGG3X#3U%_<$-4+!&D_GR#/ M;"L//X'5-85%WF4!?ZKC43<0DQ$^Y(HNS1DSOY(KWPO1'("[X->I3^??M7!+ M$&#JNZ"OA4-=H8O89HD"CE *7!9HFS,:1#Z:/: U2GPT;DS;L=/;,3+(HX3= MT^#>!P Q4-3< TPM&QX4.LN8-GQ)O^L^D[ID#&3P(FA!S QJ\AO=)8_&XNW! M-H-Y3ZU V+3%83HT"."+Q7CF9TU\U.R8?/'NR_7YX+KQ[LMH].7S"1D[8-T2 M8_&-!)YC6Z>$5T!=7)X/L.P)(]$'CTZ:I7KZ>4&GK#'V&?W:H!,P?D_ 6+ZE MR^#G)V7KU_NWVW'V'=4G&S(Q.ZV"[3?VPM";;V E(NG_;3>S_WE&I!#Q3U)C MA:!T%F@O. AQ>N3I-1LRJ& M+;+7?;F"H2GXW<19NWM?9_9R84LZ^Y$N73+P M;?-K@&;&%2PAMH4UH;B O1]\2=:L%6YS^P5S3LQZ$9?VN<^"=;:IG_[!R(SB M:@PT6HH)/ LW^&R"V5I<&$4_2,#^B:!K."I1!TM&_09&)!KX&YF*7#8LK'Z< MW<:+,LM-(\#.&:%8-(NZ@[$?@"D5!03T9\]I"$LO^1+YL+"C J,Y/BJ(,ZAF MG$&]I1.8*1P0X) QII?A&O@>6AD)RP!;<4C^P.@)!E3L('M#E MPY70!^@3]B+ $(\P"6RT5<#?%',MM&3J\MPB5@53G*G#95D+5]*4O$GP !_- M0VY5NB;8MC;._= &9F(ML44L!@!9&@$+!D9SY% ?+)JDC2S)F=^(G#E7:^%# M$PS>*:@&4/[*PJT:,=_'N0]QMV,K^0\TX^F5 M8[$;VP1Q ,*Z.C"XYKE N2 "NQX@#7TJK&_;Q2D38VZH1K RQQ[UK41] 8^R M@5T+CQ,N"/))M-0PCC$Q0HZ <^@L_!/9-]3!":&4I"*E7&P8M!;6 .?/0=5 M8$]=TCXTTK!%\?GQ\_B=&'+TV0((A2,1>$DY7;E-2UU89IQD(/JHQU?O^Q^O M7^-P:_<.VS\=DI$7PB5/Z@/&*8:GR0%%2&WAOC/.[>T[,[ MI,8]E9?$,+^(7L,L(#H]HS=\JL"_;CU^MYE6>Z 6U[N:%C DTYB5E83$R!)KP]-.%747F8!/:#='X(#8K\3_'*1#)35 M!Q>FQIA .76QG(MN!W).(DKD$U] MOJ.% Q-!V_E??^!#K^C7A!M]-"=!#.IT!E9HHEB8K*R@,?%AHH?Q "O(4W>)%;)#+N%W3%S37@@FW: MB]S:GQ]6 M5^CWC8VA2FY#> MXGAW,"1U[435.CCT.2YW7*G M1%Z27KC M#IMW+KQ;;EVLV'C =L:G36%WI\\4 M@QG'9/IP0(5K/AXI9>J'=7K,)L(9R54@P 0<)TFX?\_$&OF9+DG+$($L,7,[ M@9>.#12'GC%GPY"@(,F!HSA1 RBV\,(XU9(0J M4>S*6HF("T,UWB%!P;.YH3T(A_MQT=MWG=DC@D[S": M4< 9KKGWN<%*."!9RD(Z+4]2X69V( MT#Z,;S/3.2GN9&SLA\M%'!+)V4F)OY=K%YA4]\QE7"S8H6*RF$1HJ:B4BTJY MR("]2KFHE(N$?#^-6^,WB&NNEDLZA:F.O[1+4P*]#9O\J$7@\OP(?E$G0G,@O IK/^P5J]; M11K>S4V.8&8O%NA3\Q+-3KX*+354H\74IQ9;\S6XS53H3FKUI'6CL8O0@CF) MEYJ@]Y%K2EH[(<)G,VAY&AS(V]:IB#B"]7<$;E0N:X,!!X[ PD?WAYI@* >9 MW9Q98]B).<;7H3$VCU"B&&Z[":\<# _S W[U5@DH G9-95E@0@>-02>M3Y"#\G/NC)CWA$1",6#2EO3HAA M"&\^!^LI;A+F"-S 9&"PHM)%FK/$>!&:D[D0($7C,+T1C;-;05[.T20N MS-UQZ.J*X['F+,3/Q!YAG(RS(0W3Y3J7;UUJ/X%!#S3U/5 X=#SPL.%PXV*& M=^0_Q-Z8P- C$G.V3$#X_:&E8TCC+6,&2^VHF5N#J)\[V"[SY/=4('Q%F:? M7T5MO4A0R(AE"6$N37!AVF9RRB:GRB.9:E8KKU4O9S-V+ZL)J]]R%$Q-@7Q]G96KME. M'R/;@E^9S-G_#W%F^0'O7A-Q&<#49S"=83 /KL!-LK RW-A>%("G%PN- M.RX2-CS+F*PH8O+\\2@MVL1/?NSF:CBY/QZ3"IXXL?ED PW&_!! MH6C@2@""#XPX*C).=LND>5Q^=)=(N<:-XT&%_!9?&L3) ;$JWI, *,T[\P0_ MQ5 '-,)S10C#20T(#,_BXRWPGRWP>\&0(V4[OR5@27J&#G7!_N2GH;WW7)CV M&:+\'K/"W(QA8PP%2$SWHC?$IY\9UH]2GC"+^V0F?;H5?4JVC8>DXI&TT&\=ZLW'4,73RZ@(C MBJ(RESJOA2T3?,56_NW%E:]%K<"(&')!?:Q4WYO%G\03X8$CXCGA^"I(4E5;LF134%AZKU=* AYI3M2RH$%@>C"1-9OM7J?9D3#+D)ZH MPO-:!?09VHI/G6MQ&#WODO&1 MV]0Z,.4E#4C;B#.%6/-B)R].P^4/YG 9LX)D8/2QZL +D_GDLQ=?E"M.,&W? MC.QPI<3(\NT;/@XSJYIKQ,=Z(I\O4*)X0_R.B8/$$N;BM;@>\;8D;I[A$!O2 M7'>Q:K15)?+JC!5%OIG#/3"D,W?H,/=$U*2%WWB+N.P".LJEX#Z5V#F".<:[ MH6'.F2@4HO3?C89O@R@EYEH<"KYA_L'9Z#,,B@@8C((P\WCUA'LXKU$G"=ON M2AM@CB&)7SSA^7%5B;9R?Y8#%9^?V^Q13_W7#T:W?1H_^3WU?3O. &4/(;]Z MZ&2+>@O47U+58&=!@ISG5 A3I+$&T$=,!HL/E'C\87+$X5D;D;OA \>>SM(/ M'&\*QF%:FY(E 7E-G3>?HPR>5@$)3W'$"YF4NC8QYF$+2YAYV MW@EH6N25?,$-WL@U\Z.,%^S.%P[[EC0P*Z[$4 ;.0\R:%O*7\;ZIDMP6/(#W MV,9'6?;4#N.R*?@G'[HH!#CX!]A?WX/)"3^)>]+PW 9M8)A#2\99,J&@!XLF M6$&Y[Z]RG*!\>@!$&Z;'-XRY4XFPF+(_D$=A(L,<,0[!3T6R3V:7FZ M<,&+E\#XX0M@:F^80!,,<, :>0L&1L.)LRE!TB]1=!4'>.:,NK%=/8P#.\UN M/W$0X:/(%\Y97VS!-XY;+;XLIU<;@Y*K!]_,&77!0LAN:_,5_*XF39F+[I>S MQ [QVF,O+DDB&!Z&*V+G,$NNBF^S[>48QDE#>K'A@7%P'D +,(EF8CA8(TLO MXEO0^29">[*\3U5C9E(L8^7E\[&.T>,&)SHQNH'C2^V '&!T"?\-9E[D6/B; MB'X'^"O/*.(O67EUH,69%1+GO43=9.BEGQ^8R9/0@'8M_H 0]T>%_)F^]W?R M?&P:F&<.?R[\'2=[^._IKCYQ$[/LI%%)91_\$;:49#."!QPCY-.23'740BV;T2/Q 3 ;3*O^MTT].$W/F(BMC(()*:A4,: M8);@4<5OMG ATL3E:=;27*T@^D,+].5L%N)B]8P( HJ+W07_$:5SBGC@2+N7]1)\V*>Y>1#B \-(TTXI3H8-5(TG#16!(I(,<]!+S MV5:A(R$IWH&WKJ]\!"77^CQ0&!K 602/[$57!\G.)%F?D^NR+#%_-)B"+-1 -=.@==\0TR>'7>Q,Z[ZQ[Q'5L*;Y;#%O@S\ M]JGAJ,21CK6:$QG@G,]*:H1QHUJ>:3V>R9EUQP2153]%8YQC^:8I/KGY=A!7M&/]"5]J MQ=24'^->P(2K*C9[62PP?7LLI*WT#.L6W) 8>N,_&O[\+;==R8]-YPDOFA8G MVG:M?67;P[77O?>_.YS:?=. J*B3&'VISX,$[&@#5- AS1PL)Y M+>=;KRH)[[A3H8+7?)=Z;KGFL>,Y7.1B<,4SL>B!#ZVT\HN+3.H55A#8IF>^ M\<.\XQ.ULWJ$9&H8B4D1M/.!SU.%4[AW< 0/>7@Z9Q<(<]6#@C<6LO;!E\NH;9>S@BP[^&H\'G M(>E?GI/A[^^&%^<7_>N+P?!9E)6IB^]ANF$NIN+@-[Y><4-XF!FG0.LOR9;^ M8&_[^XI;UEX4X$$%&E9B,Z M'@TIMCMC ?CKO>M4Y%(P\@&PIS1]HZMY\33A M&;2'SQGL!/?W^G0S!YJ6B4QL-PNGF(,<) >KR\+Q]L]0?L%>*T4K12M%*T7O MA\C:*;K&"W!Y/.0'G?^7BXBDB)?[:B6F3L8;0]]$9T8S/*HJ?NO$ -^(LG-= MU@.^HTWT)??&D)UC5^/A?M]<_FAJ;-,_NO1N\%T\.]>;@NI!J/K1%#<8[EQO M"BHUJA14"JHZ0E5C4^8E3-_F5OF#+RS:N585D I(!60&I+%SK2H@U8A40$HR M(G=N8(FJC)].=\"BR63W"8!==%^I7JE>J5ZI7JF^TJJ_;VD_'5/SZY0?%-\ ME7C^R0^FR=ADLEK"NJ4W0:>O29="3Z6RRPW%\A;]>"?;GAS6\Q$A>*31UGI& M1T[5U!D673OJ&G*JIL:P'&M'AD)%-E2:':W=.Y)3-36&Q>AHS4YWYZIYHG4R MX?^]B'7RWA.'B,EIH3RPLT\&&_LI+7T*BF MUE+NE6+'78&9GBYG8.8[0M#59:I$5*QJ84:M92NH:R-;05T;V0KJVLBN%]3R M!EF_I*]RP'/#W8 %)U)H;.>RZT706LM64-=&MH*Z-K(5U+6172^H9:UY3<^1 M%[M^AX %V)5:\LXQ_M(4:LUMU^8OG;)OF!3JW+GLC57*:[VNVNQ3$2@[305E M1:!L]XHY[]JILPI0=K1V20ZR=NJL I1MK=TNUAI(;LF]6%APS9*[9@&C/KZ% M%2PXB]TPQUN(-_?*0HOXB36NCS"T3D?5W2ERW$&.]G%/D4.1HYP<+:.ER*'( M44:.EJ:W5<6N(L<=KNU12\X=;]*'2%N\U2/^IG.OD()7))>'Y. I-HO'C\A MUWI73YOB.B'5UF2H1 M%:M:\U)KV0KJVLA64-=&MH*Z-K+K!?6>!%\O7-.;,_+*\8+@-9G U4DDUG/E MB\#*R-LG1$+:/57.6 DHVYUB(4'ME%D%(+O&[D_OKK7LS4VNQ^UB#J)VZJP" ME*^:)6&_M$=/.?'_M8K6226[7AY K64KJ&LC6T%=&]D*ZMK(KA?4LD;K,$ 7 M,I\%(;'C2%U<'OE:@QODVWPD(U<;=#[919!2!?&?=LXW_1,-O632AN.?'DYL2#SV^8RX( WTMY=75% M'(^Z\J!;!68UY.A.764K&"LA6\%8"=D*QDK(WIAKJAV5G$*AXEU)0[^$,^9G M4:XX["5GL*O&FW->%2O9[MV9L[_.>HU!;LIYKH%BQLZ9T7KB\%?,J LSU*LM M%3/N.#A4SL/75'F@+++K57)0:]D*ZMK(5E#71K:"NC:RZP6UK.'2\LV\8S;Q M?)84#(;T6W*DHA2ZW+GLS6TYZZHM9]6 \DA70%8"R&[)\?^U4V85@&QKK?8] MNT#KHLXJ0&EH[>[N7QBDPGRRR*Z7ZU!KV0KJVLA64-=&MH*Z-K+K!;6L8;XT MLB=S+*_&E0VOC">6-JAJR+U$^8GED KE?43YJ2_S4BCO)-0GD?4>X4 M3_?<,,HJK"B+['JY*K66K:"NC6P%=6UD*ZAK([M>4&\@K/BY?_WQXO(DK?=+ M:OY.R6CPYZAQ<7D^N!R=B(^V%(*\9,D9A%(H]4$7IP4JLKQH[+#GV?<_/LM= M*4A]8D5A\^&-E2VU?6[OD>[T'MXFJ7#>?YS+WB^B<*X>SFVM]8CL@$)Z_Y$V MM+;Q\,ON=X&T"D7*(KM>[DVM92NH:R-;05T;V0KJVLBN%]3R5CAFX46R8-"\ M&?7E"S0JAE9?W0KJVJA;05T;=2NH:Z-N!;6DUN2+O?)%Q&UMUV)N>"*.QGE' M ]N40FFELC<:]'YZ4%L_+,E>2*&86H.B%XO4I5!,O4%11P7)!XJASHJ1#Q1] M]Z#(&N\JL5#.;2<*F:7X=/<@5S.O?* H&T5&4-1(D0\4HUC:*X5B:@V*OGM0 M5-V6+++K%;VKM6P%=6UD*ZAK(UM!71O9]8):UCC6P=D0"[4"$@7,(K:;U6X1 M$&5&#@UMSPU.I%#BSF77B[.UEJV@KHUL!75M9"NH:R.[7E"K2JX] VRC8?!F M5^MTBP=2U$Z?%<&RV58YV6I@>:0U)4A0U5KV!L=EV]C]:[!J+7MC6'8T0X*Z M%UF#@OM8W+:7-#S6])Z:4JJ!94_K]HIO$:F=/BN"94N9X)7!\KCDC2"UTVNW=ASE4O9\LLNL5XZVU; 5U;60KJ&LC6T%=&]GU@OI[0GOP&;3/_>6@ M::1Z>BC.]^'+Y:@QO/COX(3P9A/^P8?^YXM?_SHAZPTGN==1G)*2VL?;6A5CEL@N9_IN([I(/VL(')5V//MYC/ ML;;=Z8G.L>2H%D3']-#UGPX(\G-!+0ON^>5 /[@+Q8,56L\6XYF?-?$!!JS& MT&X2^YT[/WK+Y69_-?#)B04B& MRR!D\X!K-%OSN4M>TX<]K%D1.&+Q] M X]Z^R9Y[N/)(8,*_DU=Z..2=#3>N[WNRQ6,6,'O(^)-2/>^SNS].%Q_Y%:F M:@G6U03@_N#3-4SLPQ$9_C4<#3X/2?_RG Q_?S>\.+_H7U\,AL^BK4Q=O,9) MQ[0=FV\A0 I_[/>O"(6)Z-)S&_R/=,[9T[Z^LET2SKPH@%X%&F'?3 :4S?90 M6#2DK_>N4Y%+(PO,9.LI3=^R_?[RGLK,$IY*!DF9U[+3EBKE*.4HY2CE2!#4 MJ/@B4.ZJ/^?=]LDRFV%LZ%M=SDZJXJK5 -LFGD=;A7-H M?Y,&S!I/"/?-T(_FS#9YI'4](R%%1[ )4:50HJ!54% MH:JQ*;--6[BY5=XT]6:S5)OKK_,U\'6^M1KS"E0%JER@&@K4ZH&J1FH%095N MI.[<.).@8/+^E$#UNJ]4KU2O5*]4KU1?:=5_QV;*Y(XM'8S+"]3<]*WF4FBK M5/:.W\'1TKI-=<:1;*AT>KO?*"V=[!UCTC6Z?'[#7!8$ MN#'RZNJ*.!YUY2'%X_*74C!U SG6A,*-QR4]ZS9#*#(H,B@R*#(H,B@R*#*L MD>&5H1T=%[W1>QGQE.CJ:\E#D>E9'A*G2M?@;@'-'?8\2!X,>#\D[VD) MBDY)L&.=7BTUX>PENH;6/"XF:A6Z54&WW2J61BATJX%N1^N5)/05NM5 U]!X M(;R$Z'Y'B+.Z5)/(N:AJJ6:M92NH:R-;05T;V0KJVLBN%]3RQ@O78H7\L%Q+ MO%U4')HKA?ZJXL7HAR5UM#(X,0K<38!;\A)C!6YEP%4CM[K@&BHN7%UP=3G! ME; J<.\%MUGG&KN0S@ MRALM'*+A%Y (-SK;KGB#V(I1&! 0:D8.W_Z\CVS=?0Q\DQ1O'FMZ3\U@BA-Y M3O2T;D^5L"I.K'*BU5;!:\6)54X8U3?V@\_]R^_A?EDY%^1)Q M79+&/8KR=[5U^P7:#6R+^.*MJ-[Q61 Y87!([A0SL5WJFC9U4CGAC)'WWAS4LL2L1D!" MC[ ;ZD0T%%^",IGO+&UWFCR?M\U;,)^&^"G\ BV WIL,#]S%>\918.,!O(=D M!'\Y]MP.Q3L4^/?0DD0Z_!K.*+0Q).R;Z406- !H-$\^AG:98;Z-/P?$C'P? MNPUR;<_*=1&EP0-SXN"O,0M"0BT+VHXYFS'V$EN]V@P77_4P!N7PVV[M<)97 MW2MLP-R#!UFVS\S06?(W0U"?CATF5%]0[&O>]X E?X/60!!""<*H:7J^Q37& M9?%'H%;G= DR)A/FB\.,<[0(9Y[%3S3&FR.7JQYO 29X/O\KBCOH07-]T4+7 M9L$ACIW-,_KO* CMR?(T&:%D.V+B@?,'D(HY-KOAI,RKE;DSKDC;O0&H/3_X MUP^]IM$])71L.W:X1$+[[,8&40BC4,LROBA(J2KTC5<$5.R0"!8 M0T":9!G M8'HG-)M.Q0A$'";41'DX; 0Y[ &;,IXP=;TYF0H*MSSRX%^B!RL4GRW&,S]KX@-LN#?+.W: *KFH#AD-_APU M+B[/!Y@'_4&/N,?FW0"6!\0JAS2Y?!SV>/XF_\O/7^ M58(2N9'_?!ZLS#F=UETE#-\_[>3'+F@W"'W/G9Z]9?.S/IOY9(0QEN$RX(&; M:QZ/",B0F1ZXQ;]%U ?HR0<[@(:1IMYLP>])L.1:N,%OW\"CWKY)GOMX?N96Y.EEDC=9+ MQYS3A35!N#_X= TS^W!$AG\-1X//0]*_/"?#W]\-+\XO^M<7@^&S>"M3%]_# MG(-OZ;4(_,;7,HIE^>^HPX.$PQEC.-WL:2]?V2X)9UX44-<*7N]=ZR.71A:8 MQ=93FKYE>_WE/9.9)3R3S/Q^>2]E![Z@4K12]-[W6DU7I> ^6#J=K@%;7%XN MO1LV'X.KT=*UG2M/X?4@7OUH&H'?V#(46GN UF>ZW#54-9Y\RZ-V]Y2%/9HS M>>9MDS]-O=G199 MJ5ZI7H89L5K]K3G<.Y>M5*]4+^$DMV6S[WV\?P0 8&%P(H52:LZ)GJ MEVHFW.4IAVEYD)B2W]-@QGR;Z@#$V@@A1)+96_TF/JG'Q!D]+1> MMWAHE!2JJ3$LK2/-:'?E5$V=83&T=F_WH^5[*NE?<#8>SCP_;(3,G\<[7N=R M3\42;?UX_/S=U;I&\<#8VNFS"E@VY.A.7657!\8]L=9'/K7$Z2'B&(CXM @\ M<@47_I8.WU6 V-8=C2] M8^R\3WOB65SY;$%MB[!O"]QA&61.ACS,B)^X5I6Y#T=\/J=B-.%QKUFZINN[KY?X#O>H@N!*3*PJ=KFNLA74 MM9%=+ZAE]3HPOH;OU B7/*Z&9;8++.U2R?K-AWVUYI&*X%<$RE93)=8J F53 MW_VHE#47ZW_8A>4]*^'6U3OOA8I&6FJGV$UY#ZW1[ M"MZJPMO46DTYX?T.IZFZ7)/(MJEJLJ_6LA74M9%=+ZCE#<$E)TK_>M%_=_'K MQ>AB$+]B[5/_>O#IRZ^PU@]_)H/??K\8_27A>=.*PK51MX*Z-NI64._!PE0M M1>Q<=KUX5VO9"NK:R*X7U/*Z.*JE%+HKE;WK\[6UX[;:D2T?*JV2HC I-%-C5-J:<;S[ MDRADM?R+,[ ?L>Q ,'E9)9&Q\/@B0:USI(ZAK0B4[:Y:@2L!94L[DN#-$'MB MHJ]O6W/;%A60U0#R6+W=ZI$KQOLH "4R MGUALX05V* X9MMB$^3YX&CZ[86[$I%X\:K:7"0RB7M$@DF$WDR+$C@C1/"X> MR:((45M"@/=K%&-J,A!">C>J[ 3BG!,E';,E(O S-FGK6K>M(FZ5P/)8ZQVK MB%LEH#0,33?VVH&J(+@2$ZN*7:ZK; 5U;637"VI9/8\'V MJO.M!(Y'NX\H2NPW\-.'94Y.U"SM5G+HN0PY-\6&W;!!SA-G%1MVPP8Y3R>7 MU>%[796'KPJ6^M'N]TO46O8&$_&MUEZ[0!4$5V)B5;'+ M=96MH*Z-['I!O5]HNQZ0;U7WE0N@<-/ M&=A'[VJ_7E"G7B]9:7C5ZR4K#:_DKY>$'W@,\!E^FI.0OVWMJP]?+D>-X<5_ M!^!ZH73"/_C0_WSQZU\G9%T^^=R__GAQ>8+KR"G)*7YX'(D=',@ M);?>CCUK>?;_ 5!+ 0(4 Q0 ( $>#)5;K/59$B 0 (,6 1 M " 0 !A96AR+3(P,C,P,3 U+GAS9%!+ 0(4 Q0 ( $>#)5;; MR&+7VP$ (L# 5 " ;<$ !A96AR+3(P,C,P,3 U7V-A M;"YX;6Q02P$"% ,4 " !'@R56#KOM))$" !$" %0 M@ '%!@ 865H&UL4$L! A0#% @ 1X,E5K(A MBG<'!@ =S< !4 ( !B0D &%E:'(M,C R,S Q,#5?;&%B M+GAM;%!+ 0(4 Q0 ( $>#)5;XSVV'A00 (C 5 " M <,/ !A96AR+3(P,C,P,3 U7W!R92YX;6Q02P$"% ,4 " !'@R562JD# M^/L. 16P "P @ %[% 865H>#DY,2YH=&U02P4& < !P# 0 YE end